Refine
Document Type
- Doctoral Thesis (28)
Language
- English (28) (remove)
Has Fulltext
- yes (28)
Is part of the Bibliography
- no (28)
Keywords
Institute
- Biochemie, Chemie und Pharmazie (28) (remove)
Bei ca. 95% der chronisch myeloischen Leukämie (CML) und 20-30% der akuten lymphatischen Leukämie (ALL) des Erwachsenen liegt eine reziproke Chromosomentranslokation t(9;22)(q34;q11) vor, in deren Rahmen das BCR (Breakpoint Cluster Region) Gen auf Chromosom 22 mit dem ABL (Abelson-Leukämie-Virus) Gen auf Chromosom 9 fusioniert. Auf Chromosom 22 gibt es zwei verschiedene Bruchpunkte, die somit zur Bildung von unterschiedlichen Fusionsgenen führen. Bei der CML findet man den sogenannten „großen“ Bruchpunkt (M-bcr), während bei der Ph+ ALL der sogenannte „kleine“ Bruchpunkt (m-bcr) vorkommt. Das hybride Fusionsgen auf Chromosom 22q+ (Philadelphia-Chromosom) kodiert für das jeweilige BCR/ABL Protein, während das Fusionsgen auf Chromosom 9q+ für das reziproke ABL/BCR Protein kodiert. Das ABL-Protein ist eine Nicht-Rezeptor Tyrosinkinase, die eine wichtige Rolle in der Signaltransduktion und der Regulation des Zellwachstums spielt. Im BCR/ABL Fusionsprotein wird die Kinase-Aktivität von ABL, die im Normalfall streng reguliert ist, durch die Fusion mit BCR konstitutiv aktiv. Dadurch kommt es zur Deregulierung intrazellulärer Signalwege, welche die maligne Transformation hämatopoetischer Zellen verursacht. Eine zielgerichtete Inhibierung von BCR/ABL mittels ABL-Kinase-Inhibitoren induziert Apoptose in BCR/ABL transformierten Zellen, was eine komplette Remission im größten Teil Ph+ Leukämie Patienten zur Folge hat.
The Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes high fever, rash, and recurrent arthritis in humans. The majority of symptoms disappear after about one week. However, arthritis can last for months or even years (in about 30% of cases), which makes people unable to work during this period. The virus is endemic in Sub-Saharan Africa, the Indian Ocean islands, India, and Southeast Asia. It has additionally caused several large outbreaks in the last few years, affecting millions of people. The mortality rate is very low (0.1%), but the infection rates are high (sometimes 30%) and the number of asymptomatic cases is rare (about 15%). The first CHIKV outbreak in a country with a moderate climate was detected in Italy in 2007. Furthermore, the virus has spread to the Caribbean in late 2013. Due to climate change, globalization, and vector switching, the virus will most likely continue to cause new worldwide outbreaks. Additionally, more temperate regions of the world like Europe or the USA, which have recently reported their first cases, will likely become targets. Alarmingly, there is no specific treatment or vaccination against CHIKV available so far.
The cell entry process of CHIKV is also not understood in detail, and was thusly the focus of study for this project. The E2 envelope protein is responsible for cell attachment and entry. It consists of the domain C, located close to the viral membrane, domain A, in the center of the protein, and domain B, at the distal end, prominently exposed on the viral surface.
In this work, the important role of cell surface glycosaminoglycans (GAGs) for CHIKV cell attachment was uncovered. GAGs consist of long linear chains of heavily sulfated disaccharide units and can be covalently linked to membrane associated proteins. They play an important role in different cell signaling pathways. So far, solely cell culture passage has revealed an increased GAG-dependency of CHIKV due to mutations in E2 domain A, which was associated with virus attenuation in vivo. However, in this work it could be shown that cell surface GAGs promote CHIKV entry using non-cell culture adapted CHIKV envelope (Env) proteins. Transduction and infection of cell surface GAG-deficient pgsA-745 cells with CHIKV Env pseudotyped vector particles (VPs) and with wild-type CHIKV revealed decreased transduction and replication rates. Furthermore, cell entry and transduction rates of GAG-containing cells were also dose-dependently decreased in the presence of soluble GAGs. In contrast, transduction of pgsA-745 cells with CHIKV Env pseudotyped VPs was enhanced by the addition of soluble GAGs. This data suggests a mechanism by which GAGs activate CHIKV particles for subsequent binding to a cellular receptor. However, at least one GAG-independent entry pathway might exist, as CHIKV entry could not be totally inhibited by soluble GAGs and entry into pgsA-745 was, albeit at a lower rate, still possible. Further binding experiments using recombinant CHIKV E2 domains A, B, and C suggest that domain B is responsible for the GAG binding, domain A possibly for receptor binding, and domain C is not involved in cell binding. These results are in line with the geometry of CHIKV Env on the viral surface. They altogether reveal that GAG binding promotes viral cell entry and that the E2 domain B plays a central role for this mechanism.
As no vaccine against CHIKV has been approved so far, another goal of this project was to test new vaccination approaches. It has been published that a single linear epitope of E2 is the target of the majority of early neutralizing antibodies against CHIKV in patients. Artificial E2-derived proteins were created, expressed in E.coli, and successfully purified. They consisted of 5 repeats of the mentioned linear epitope (L), the surface exposed regions of domain A linked by glycine-serine linkers (sA), the whole domain B plus a part of the β-ribbon connector (B+), or a combination of these 3 modules. Vaccination experiments revealed that B+ was necessary and sufficient to induce a neutralizing immune response in mice, with the protein sAB+ yielding the best results. sAB+, as a protein vaccine, efficiently and significantly reduced viral titers in mice upon CHIKV challenge, which was not the case for recombinant Modified Vaccinia virus Ankara (MVA; MVA-CHIKV-sAB+), as a vaccine platform expressing the same protein. These experiments show that a small rationally designed CHIKV Env derived protein might, after optimization of some vaccination parameters, be sufficient as a safe, easy-to-produce, and cheap CHIKV vaccine.
Epigallocatechin-3-gallate (EGCG) is a catechin found in green tea and was, in this work, found to inhibit the CHIKV life cycle at the entry state in in vitro experiments using CHIKV Env VPs and wild-type virus. EGCG was recently published to inhibit attachment of several viruses to cell surface GAGs, which is in line with the role for GAGs in CHIKV entry revealed in this work. EGCG might serve as a lead compound for the development of a small molecule treatment against CHIKV.
The human Long Interspersed Nuclear Element-1 (LINE-1, L1) is a member of the group of autonomous non-LTR retrotransposons found in almost every eukaryotic genome. L1 elements generate copies of themselves by reverse transcription of an RNA intermediate and integrate into the host genome by a process called Target Primed Reverse Transcription (TPRT). They are responsible for the generation of approximately 35% of the human genome, cover about 17% of the genome and represent the only group of active autonomous transposable elements in humans. L1 activity bears several risks for the integrity of the human genome, since the L1-encoded protein machinery generates DNA double-strand breaks (DSBs) and is capable of conducting numerous genome-destabilizing effects, e.g. causing deletions at insertion sites, disrupting or rearranging coding sequences and deregulating transcription of functional host genes. On the other side, L1 elements have had and still exert a great impact on human genome structure and evolution by increasing the genome size and rearranging and modulating gene expression. Furthermore, due to its endogenous and generally non-pathogenic nature, L1 is a promising candidate as vector for gene delivery in somatic gene therapy. The structure of the flanking regions between de novo L1 integrants and the genomic sequence suggests an involvement of cellular DSB repair pathways in L1 mobilization. To elucidate the role of DSB repair proteins in L1 retrotransposition, I disabled DSB repair factors ATM, ATR, DNA-PK, p53 and Ku70 by knock down (KD) using short hairpin RNA (shRNA) expression constructs. To inhibit the function of DSB repair factors PARP and Rad51, I used dominant negative (DN) PARP and Rad51 mutants. Applying a well established L1-retrotransposition reporter assay in HeLa cells, de novo retrotransposition events were launched in order to test L1 for its retrotransposition activity in the context of altered DSB repair conditions. I could show that L1 retrotransposition frequency after ATM KD had increased by 3-fold, while ATR and p53 KD reduced L1 retrotransposition by approximately one third. Unfortunately, the cytotoxic effects of the DNA-PK and Ku70 shRNA expression constructs were too strong to determine potential effects of DNA-PK and Ku70 KD on L1 retrotransposition. Inhibition of PARP function by expression of the DN mutant and overexpression of wild type PARP were found to increase L1 retrotransposition by 1.8 and 1.5, respectively, while Rad51 DN had no detectable effect. Interestingly, overexpression of wild type Rad51 seemed to roughly double L1 retrotransposition frequencies. Since in my experiments KD or expression of DN mutants was time-delayed to the onset of L1 retrotransposition after transfection into the cells, I developed a temporally controllable, tetracyclin transactivator (tTA)-dependent L1 retrotransposition reporter assay which will be of great value for future L1 retrotransposition studies that rely on temporally controllable retrotransposition. Due to a previously published hypothesis of L1 playing a role in brain development by contributing to somatic mosaicism in neuronal precursor cells, I generated a transgenic mouse (LORFUS) using the tTA-dependent L1 construct to further test this hypothesis. LORFUS harbors a bidirectional cassette driving simultaneous expression of a GFP-tagged L1 retrotransposition reporter and beta-galactosidase. It was bred to another transgenic mouse line expressing tTA in the forebrain. The double transgenic offspring was used to characterize L1 expression and retrotransposition patterns in the brain at postnatal day 15 (P15). General transgene expression indicated by beta-galactosidase activity was found in hippocampus, cortex and striatum, while retrotransposition events revealed by GFP expression were found in hippocampus, cortex, striatum, olfactory bulb and brainstem. These results suggested L1 retrotransposition in the granule layer of the dentate gyrus earlier than P15 and migration of cells carrying these events along the rostral migratory stream into the olfactory bulb. To facilitate the use of L1 as gene delivery tool in gene therapy or genetic engineering, I furthermore intended to manipulate the L1 target site recognition to allow the site-specific integration into defined genomic locations. To this end, I performed crystal structure-guided mutational analysis exchanging single amino acid residues within the endonuclease (EN) domain of L1 to identify residues influencing target site recognition. However, individual point mutations did not change the nicking pattern of L1-EN, but resulted in a reduction of endonucleolytic activity reflected by a reduced retrotransposition frequency. This suggests that additional factors other than the DNA nicking specificity of L1-EN contribute to the targeted integration of non-LTR retrotransposons in the host genomes.
In this research project we aimed to generate genetically modified megakaryocytes and platelets, by targeting protein expression to their secretory alpha-granules to delivery ectopic or therapeutic proteins, to be stored and kept there until an external stimulus triggers platelet activation and platelet secretion takes place. During platelet activation, the therapeutic proteins would then be released to the extracellular space, either as a soluble protein or exposed as a transmembrane protein on the cell surface of platelets. For long-term approaches, genetic modifications must be introduced at the hematopoietic stem cell level.
AIMS: As first approach, we aimed to characterize the lineage-specificity of expression of six different promoter fragments in lentiviral vectors: the murine platelet factor 4 (mPf4) 1222 bp (-1074 to +148), human glycoprotein Ib alpha (hGP1BA) 595 bp (-265 to +330), a short and a longer fragment of the human glycoprotein 6 (hGP6 / hGP6s) 351 bp (-322 to +29) / 726 bp (-697 to +29), as well the human glycoprotein 9 (GP9) promoter 794 bp (-782 to -12). These promoter fragments were included as internal cellular promoters in self-inactivating lentiviral vectors (SIN), using an enhanced green fluorescent protein (eGFP) as gene reporter. GFP detection was evaluated in vitro (in transduced non-megakaryocitc blood cell progenitors and in-vitro differentiated megakaryocytes) and in vivo (Bone marrow cells, blood cells and spleen cells). For targeting of proteins to the secretory alpha granules of megakaryocytes and platelets, we followed two strategies: A) The sorting signal of the cytokine RANTES was fused N-terminally to the destabilized GFP, d2eGFP (RANTES. d2eGFP), to deliver the protein into the granules as soluble cargo. B) The transmembrane granular targeting sequence of P-selectin (the transmembrane domain and cytoplasmic tail (referred as TDCT) was fused to d2eGFP or the B domain deleted codon optimized human coagulation Factor VIII cDNA (referred as BDcohFVIII_TDCT or FVIII_TDCT), to deliver the protein into the membrane of alpha granules. These two strategies were tested in-vitro, from transduced differentiated megakaryocytes in liquid cultures, and in-vivo, by analysis of genetically modified platelets by means of Laser Scanning Confocal Microscopy (LSM) in colocalization analysis (performed at the single cell level) and fluorescence intensity analysis.
RESULTS: GFP expression in blood cells from transplanted mice was significantly higher in platelets, with a smaller background promoter activity in leukocytes and erythrocytes. The highest expression was observed from the mPf4-vector, followed by hGP1BA, hGP6 and hGP6s vectors, identifying the hGP6 vectors as the most restricted to the megakaryocyte and platelet lineage. Analysis in bone marrow cells showed that hGP6-vectors have the lowest activity in the hematopoietic stem and progenitor cells (HSPC) with less than 10% of GFP positive stem cells. Surprisingly, the mPf4 and hGP1BA vectors were both highly active in the HSPC, in a range of 20 to 70% of GFP-positive cells. Polyploidization in later stages of MK-maturation of in-vitro Mks differentiated from Mpl-/- lineage marker negative cells were recovered after gene transfer of the thrombopoietin receptor Mpl, under the control of MK-specific vectors in differentiated into MKs. These results were corroborated in in-vivo analysis, where Mpl-/- mice transplanted with lin-BM cells transduced with the mPf4.Mpl and hGP6.Mpl vectors, showed significantly elevated platelet counts compared to control mice transplanted with a GFP-encoding control vector (PGK-GFP). In the Fluorescent intensity and colocalization analysis of transduced megakaryocytes with the targeting vectors, we observed a significant difference in the GFP targeting compared with those MK transduced with the non-targeting vectors. The median of the WCC values observed from the RANTES.d2eGFP targeting vector was 0.8 (80 % of colocalization) with P-selectin stained granules, and 0.7 (70%) with von Willebrand Factor stained granules. In the case of the non-targeting vector SFFV.d2eGFP the median of the WCC observed were <0.3 (30%) both in P-selectin and von Willebrand Factor stained granules. We observed as well that the GFP signal of MK transduced with the P-selectin.d2eGFP fusion overlapped the signals emitted by P-selectin and von Willebrand factor stained granules, not just in LSM-digitalized images but in the fluorescens intensity analysis as well, indicating a clear signal of GFP colocalization. Likewise, an evident signal overlap between the targeted FVIII (FVIII_TDCT) with the P-selectin / von Willebrand marker was observed. Colocalization and fluorescens intensity analysis performed on activated platelets from transplanted mice with the targeting vectors, corroborated what was previously observed in in-vitro megakaryocytes. The genetic modification of megakaryocyte and platelets will allow in the furture, not just the development of new generation of cells with advanced functions, but it will help us to elucidate new mechanisms and pathways of important cellular processes, by modifying cell function and cell interactions.
Pretubulysin (PT), a biosynthetic precursor of the myxobacterial compound tubulysin D, was recently identified as a novel microtubule-targeting agent (MTA) causing microtubule destabilization. MTAs are the most frequently used chemotherapeutic drugs. They are well studied regarding their direct cytotoxic effects against various tumors as well as for their anti-angiogenic and vascular-disrupting action addressing endothelial cells of the tumor vasculature. However, the impact of MTAs on endothelial cells of the non-tumor vasculature has been largely neglected, although tumor cell interactions with the healthy endothelium play a crucial role in the process of cancer metastasis. Besides their use as potent anti-cancer drugs, some MTAs such as colchicine are traditionally used or recommended for the therapy of inflammatory diseases. Here, too, the role of endothelial cells has been largely neglected, although the endothelium is crucially involved in regulating the process of inflammation.
In the present study, the impact of PT on tumor-endothelial cell interactions was therefore analyzed in vitro to gain insights into the mechanism underlying its anti-metastatic effect that was recently confirmed in vivo. In the second part of this work, the influence of PT and other MTAs, namely the microtubule-destabilizing compounds vincristine (VIN) and colchicine (COL) and the microtubule-stabilizing drug paclitaxel (PAC), on leukocyte-endothelial cell interactions was investigated in vitro and in vivo (only PT). It is important to mention that in all in vitro experiments solely endothelial cells and not tumor cells or leukocytes were treated with the MTAs to strictly focus on the role of the endothelium in the action of these compounds.
The impact of PT on tumor-endothelial cell interactions was analyzed in vitro by cell adhesion and transendothelial migration assays as well as immunocytochemistry using the breast cancer cell line MDA-MB-231 and primary human umbilical vein endothelial cells (HUVECs). The treatment of HUVECs with PT increased the adhesion of MDA cells onto the endothelial monolayer, whereas their transendothelial migration was reduced by the compound. Thereafter, the influence of PT on the endothelial cell adhesion molecules (CAMs) E-selectin, N-cadherin, ICAM-1, VCAM-1 and galectin-3 and on the CXCL12/CXCR4 chemokine system was examined, since they might be involved in the PT-triggered tumor cell adhesion. Interestingly, although PT induced the upregulation of ICAM-1, VCAM-1, N-cadherin and CXCL12, cell adhesion assays using neutralizing antibodies or the CXCL12 inhibitor AMD3100 revealed that all these molecules were dispensable for the PT-evoked tumor cell adhesion. As PT induces the formation of interendothelial gaps and MDA cells might adhere onto components of the underlying extracellular matrix (ECM), the precise location of MDA cells attached to the PT-treated endothelial monolayer was investigated. Instead of a direct interaction between tumor and endothelial cells, this work showed that MDA cells preferred to adhere to the ECM component collagen that was exposed within PT-triggered endothelial gaps. Both the PT-evoked increase in tumor cell adhesion onto and the decrease in trans-endothelial migration were completely abolished when β1-integrins were blocked on MDA cells. Similar results were obtained when endothelial cells were treated with VIN and COL but not PAC, indicating that the observed effects of PT depend on its microtubule-destabilizing activity.
The impact of PT, VIN, COL and PAC on leukocyte-endothelial cell interactions was analyzed in vivo (only PT) by intravital microscopy of the mouse cremaster muscle and in vitro by cell adhesion assays using the monocyte-like cell line THP-1 and TNFα-activated human dermal microvascular endothelial cells (HMEC-1). While PT did not affect the rolling of leukocytes on the endothelium, their firm adhesion onto and transmigration through the activated endothelium was reduced by PT in vivo. In accordance, the treatment of HMEC-1 with PT, VIN and COL decreased the TNFα-induced adhesion of THP-1 cells onto the endothelial monolayer, whereas PAC had no influence on this process. Thereafter, the influence of PT, VIN, COL and PAC on endothelial ICAM-1 and VCAM-1 was examined, since these molecules are substantially involved in the firm adhesion of leukocytes onto the endothelium. The cell surface protein expression of ICAM-1 and VCAM-1 was reduced by PT, VIN and COL in activated endothelial cells, whereas PAC did only slightly affect the TNFα-induced upregulation of VCAM-1. As the pro-inflammatory transcription factor NFκB plays a crucial role in the TNFα-induced expression of these CAMs, the impact of the MTAs on the NFκB promotor activity was investigated. While PT, VIN and COL decreased the activation of NFκB in activated endothelial cells, PAC did not affect this process. However, in contrast to the strong effects regarding the cell surface protein expression of ICAM-1 and VCAM-1, the effects of PT, VIN and COL on the NFκB activity was rather low. Thus, the used MTAs might also affect other relevant signaling pathways and/or the intracellular transport of CAMs might be influenced by the impact of the MTAs on the microtubule network.
Taken together, the current study provides – at least in part – an explanation for the anti-metastatic potential of PT and gives first insights into the use of PT and VIN as anti-inflammatory drugs. Moreover, this work highlights the endothelium as an attractive target for the development of new anti-cancer and anti-inflammatory drugs.
The enzyme acetyl-CoA carboxylase (ACC) plays a fundamental role in the fatty acid metabolism. It regulates the first and rate limiting step in the biosynthesis of fatty acids by catalyzing the carboxylation of acetyl-CoA to malonyl-CoA and exists as two different isoforms, ACC1 and ACC2. In the last few years, ACC has been reported as an attractive drug target for treating different diseases, such as insulin resistance, hepatic steatosis, dyslipidemia, obesity, metabolic syndrome and nonalcoholic fatty liver disease. An altered fatty acid metabolism is also associated with cancer cell proliferation. In general, the inhibition of ACC provides two possibilities to regulate the fatty acid metabolism: It blocks the de novo lipogenesis in lipogenic tissues and stimulates the mitochondrial fatty acid β-oxidation. Surprisingly, the role of ACC in human vascular endothelial cells has been neglected so far. This work aimed to investigate the role of the ACC/fatty acid metabolism in regulating important endothelial cell functions like proliferation, migration and tube formation.
To investigate the function of ACC, the ACC-inhibitor soraphen A as well as an siRNA-based approach were used. This study revealed that ACC1 is the predominant isoform both in human umbilical vein endothelial cells (HUVECs) and in human dermal microvascular endothelial cells (HMECs). Inhibition of ACC via soraphen A resulted in decreased levels of malonyl-CoA and shifted the lipid composition of endothelial cell membranes. Consequently, membrane fluidity, filopodia formation and the migratory capacity were attenuated. Increasing amounts of longer acyl chains within the phospholipid subgroup phosphatidylcholine (PC) were suggested to overcompensate the shift towards shorter acyl chains within phosphatidylglycerol (PG), which resulted in a dominating effect on regulating the membrane fluidity. Most importantly, this work provided a link between changes in the phospholipid composition and altered endothelial cell migration. The antimigratory effect of soraphen A was linked to a reduced amount of PG and to an increased amount of polyunsaturated fatty acids (PUFAs) within the phospholipid cell membrane. This link was unknown in the literature so far. Interestingly, a reduced filopodia formation was observed upon ACC inhibition via soraphen A, which presumably caused the impaired migratory capacity.
This work revealed a relationship between ACC/fatty acid metabolism, membrane lipid composition and endothelial cell migration. The natural compound soraphen A emerged as a valuable chemical tool to analyze the role of ACC/fatty acid metabolism in regulating important endothelial cell functions. Furthermore, regulating endothelial cell migration via ACC inhibition promises beneficial therapeutic perspectives for the treatment of cell migration-related disorders, such as ischemia reperfusion injury, diabetic angiopathy, macular degeneration, rheumatoid arthritis, wound healing defects and cancer.
Infections with the hepatitis B virus (HBV) or the hepatitis C virus (HCV) lead to complications like the development of cirrhosis or hepatocellular carcinoma. These complications end up in 887,000 and 500,000 deaths per year, respectively. Since the development of new direct acting antiviral agents for HCV in the past years a complete cure of an HCV infection can be achieved in the majority of the patients. In contrast, a complete cure of a chronic HBV infection still remains a challenging problem as current treatment regimens mainly suppress the viral replication and cccDNA as well as integrated DNA still persist in these patients. Several viral and host factors were described to impair the efficacy of treatment regimens or influence the course of the infection. Therefore, in this work viral factors as well as host factors were investigated in HBeAg negative chronic HBV infected patients and in chronic HCV infected patients. In the present study, it was demonstrated that mutations and/or deletions in the HBV basal core promoter (BCP), the precore and the preS domain occur in a genotype-specifc pattern in HBeAg negative HBV infected patients. While the BCP double mutation A1762T/G1764A was found with the highest prevalence in genotype E infected patients, the precore mutation G1896A occurred mostly in genotype B infected patients. Variants in the preS domain could be detected with the highest frequency in patients infected with genotype C. In patients, who had to start an antiviral therapy during the course of the disease, mutations in the precore region could be detected with a higher frequency in the samples right before treatment start in comparison to the baseline sample.
While different HBV genotypes and preS mutations were not associated with HBV-DNA serum levels, precore mutations as well as BCP mutations were significantly associated with HBV-DNA levels. Furthermore, precore mutations showed lower and preS mutations higher HBsAg levels. The HBsAg serum levels varied significantly among the different genotypes. Since HBsAg levels < 1000 IU/ml have been described as a prognostic marker in several studies, the prevalence of patients with HBsAg < 1000 IU/ml was analyzed among the genotypes A - E. While most of the patients infected with HBV genotype B had HBsAg < 1000 IU/ml, only a few patients infected HBV genotype E and A had HBsAg < 1000 IU/ml.
Furthermore, HBV genotype A genomes derived from patients harboring a) A1762T/ G1764A (BCP), b) G1896A/G1899A (precore), c) 15 aa deletion in preS1, d) no mutation (reference genome) were cloned and analyzed in vitro. An enhanced expression but reduced secretion of viral genomes was found in the preS-deletion- and the precore-variant. No differences in the HBsAg production and secretion were observed in the cloned precore- or BCP-variant, while the preS-deletion-variant was characterized with an elevated HBsAg release.
Regarding the secretion of viral and subviral particles, a genotype-specifc pattern of the L/M/SHBs ratio was detected in the serum of patients infected with genotypes A - E. This pattern did not change in the serum of patients, who started antiviral treatment. Secreted HBsAg containing particles displayed a higher density as well as a higher filaments/spheres ratio in genotypes B and D compared to genotypes A, C and E. Population-based and deep sequencing revealed large deletions in the preS domain or preS2 start codon mutations in a certain number of the viral genomes. Theoretically, these mutations/deletions should influence the molecular weight of the expressed protein or abolish the expression of the protein at all. In contrast, LHBs/MHBs were detectable and appeared at the same molecular weight in these patient samples in comparison to patient samples without these mutations. Furthermore, in the in vitro analyses comparing the reference genome and the preS1-deletion genome, it was shown that the deletion indeed influenced the molecular weight of LHBs. Therefore, HBsAg might be expressed from a genetically different source than the released viral genomes, meaning the integrated DNA.
Additionally, in the present study the prevalence of resistance associated substitutions (RASs) in the viral genes NS3, NS5A and NS5B of chronic HCV infected patients was analyzed in correlation to single nucleotide polymorphisms (SNPs) in the interferon-λ4 (IFNL4) gene of the infected patients. No significant correlation was found between IFNL4 SNPs and RASs within NS3/NS5B in the present cohort. In contrast, the frequently detected NS5A RAS Y93H could be significantly associated with beneficial IFNL4 SNPs and a high baseline viral load in HCV genotype 1-infected patients.
Taken together, the present study demonstrated that viral genome mutations as well as the morphology of secreted particles occur in a genotype-dependent pattern in HBeAg negative HBV infected patients with no need of antiviral therapy. As the amount of serum qHBsAg levels varied among the different genotypes, the HBsAg cut-off < 1000 IU/ml should be adapted individually among the various genotypes. Because the composition of the secreted subviral particles varied between the different genotypes, a genotype-specific immune-response might be induced in these patients. Additionally, the results of the present study indicate that in HBeAg negative HBV infected patients with mutations or deletions in the preS domain MHBs and LHBs might be expressed from the integrated DNA and therefore from a genetically different source than the released viral genomes.
Aside from that, the finding of a significant association of the NS5A RAS Y93H with beneficial IFNL4 SNPs in chronic HCV infected patients may explain a lack of a correlation or an inverse correlation of treatment response with the IFNL4 genotype in some NS5A inhibitor-containing IFN-free regimens.
In the recent years, myxobacteria have emerged as a novel source of natural compounds with structural diversity and biological activity for drug discovery. In this work, the two myxobacterial compounds archazolid and vioprolide were characterized for their potential pharmacological effects in vascular endothelial cells. Archazolid is a wellestablished v-ATPase inhibitor found in Archangium gephyra and Cystobacter spec. As the v-ATPase represents a promising target in cancer treatment, the effects of archazolid have been intensively studied in cancer cells, but rarely in endothelial cells. Vioprolide is an antifungal and cytotoxic metabolite obtained from Cystobacter violaceus. There are only few studies on vioprolide, most of them focusing on its biosynthesis. Preliminary studies revealed that it inhibited TNF-induced expression of ICAM-1, indicating possible anti-inflammatory properties. As the endothelium plays an important role in cancer and inflammation, it represents an attractive drug target. Therefore, the archazolid and vioprolide were investigated regarding their effects on endothelial cells.
V-ATPase inhibition by archazolid resulted in anti-tumor and anti-metastatic effects in vitro and in vivo. Archazolid was used to study the consequences of v-ATPase inhibition in endothelial cells that might contribute to the anti-metastatic activities observed in vivo. To analyze the impact of archazolid on the interaction endothelial and cancer cells, in vitro cell adhesion and transmigration assays were performed using primary HUVEC or immortalized HMEC-1 and different cancer cell types (MDA-MB-231, PC-3 and Jurkat cells). For these experiments, only the endothelial cells were treated with archazolid. VATPase inhibition by archazolid led to an increased adhesion of the metastatic breast cancer cell line MDA-MB-231 and prostate cancer cell line PC-3 onto endothelial cells whereas the adhesion of Jurkat cells was unaffected. Interestingly, archazolid treatment of HUVECs decreased the transendothelial migration of MDA-MB-231 cells. Endothelial ICAM-1, VCAM-1, E-selectin and N-cadherin are potential ligands of interacting cancer cells. Therefore, the mRNA and surface protein levels of these cell adhesion molecules were measured via qRT-PCR and flow cytometry, respectively. These adhesion molecules were not responsible for the archazolid-induced cancer cell adhesion, as archazolid treatment of HUVECs did not upregulate their mRNA or surface expression. Instead, cell adhesion assays using a monoclonal antibody against integrin subunit β1 showed that β1-integrins expressed on MDA-MB-231 and PC-3 cells mediated the archazolid-induced cancer cell adhesion. Cell adhesion assays onto plastic coated with ECM components which are the major ligands of β1-integrins, revealed that MDA-MB231 and PC-3 cells preferably interact with collagen. So next, we investigated the influence of archazolid on surface collagen levels in HUVECs by immunostaining, which demonstrated an increase of nearly 50 % upon archazolid treatment. We confirmed the hypothesis that the expression and activity of cathepsin B, a lysosomal enzyme that degrades extracellular matrix components including collagen, was inhibited by archazolid in endothelial cells. Finally, overexpression of cathepsin B reduced the cancer cell adhesion on archazolid-treated HUVECs, but also in control cells, indicating a negative correlation between cathepsin B expression and cancer cell adhesion.
The influence of vioprolide on the interaction of endothelial cells with leukocytes was analyzed by in vitro cell adhesion assays using HUVECs and primary monocytes, THP-1 or Jurkat cells. Vioprolide inhibited the adhesion of these cells onto TNF-activated HUVECs. In addition, the endothelial-leukocyte interaction was observed in vivo by intravital microscopy in the mouse cremaster muscle. Vioprolide prevented the TNFinduced firm adhesion and transmigration of leukocytes, while leukocyte rolling was not affected. ICAM-1, VCAM-1 and E-selectin are cell adhesion molecules, which are upregulated by TNF and mediate leukocyte adhesion onto endothelial cells. Therefore, flow cytometric analysis was performed to measure their surface expression. Vioprolide significantly decreased TNF-induced expression of surface ICAM-1, VCAM-1 and E-selectin, which was in line with the in vitro results. In vivo, vioprolide may act in a different way on E-selectin expression, so that leukocyte rolling, which is governed by E-selectin, remained unaffected. qRT-PCR experiments revealed that the mRNA expression of ICAM-1 and VCAM-1 were also reduced by vioprolide, indicating a regulation on transcriptional level. In contrast, the mRNA expression of E-selectin was not decreased at the timepoint when surface protein expression was diminished. The induction of these cell adhesion molecules is mainly mediated by the transcription factor NFκB. A Dual-Luciferase® reporter assay was used to study the impact of vioprolide on the TNF-induced NFκB promotor activity. Vioprolide blocked the TNF-induced NFκB promotor activity while the TNF-induced IκBα degradation and nuclear translocation of the NFκB subunit p65 was not altered by vioprolide. Western blot analysis revealed that vioprolide had no effect on the activation of MAPK (p38, JNK) and AKT by TNF, which could interfere with the NFκB-dependent gene expression.
Taken together, archazolid and vioprolide are interesting myxobacterial compounds with different modes of actions. The study suggests that the v-ATPase inhibitor archazolid impairs the expression and activity of cathepsin B in endothelial cells, which leads to a higher amount of collagen on the endothelial surface. As a result, the adhesion of β1-integrin expressing metastatic cancer cells onto archazolid-treated endothelial cells increased while transendothelial migration was reduced. Further, archazolid represents a promising tool to elucidate the role of v-ATPase in endothelial cells. Vioprolide was able to prevent TNF-induced endothelial-leukocyte interaction in vitro and in vivo by interfering with NFκB-dependent gene expression. Further research is required to enlighten the underlying mechanism and the direct target of vioprolide.
The endosteal bone marrow niche and vascular endothelial cells provide sanctuaries to leukemic cells. In murine chronic myeloid leukemia (CML) CD44 on leukemia cells and E-selectin on bone marrow endothelium are essential mediators for the engraftment of leukemic stem cells (LSC). We hypothesized that non-adhesion of CML-initiating cells to E-selectin on the bone marrow endothelium may lead to superior eradication of LSC in CML after treatment with imatinib than imatinib alone. Indeed, here we show that treatment with the E-selectin inhibitor GMI-1271 in combination with imatinib prolongs survival of mice with CML via decreased contact time of leukemia cells with bone marrow endothelium. Non-adhesion of BCR-ABL1+ cells leads to an increase of cell cycle progression and an increase of expression of the hematopoietic transcription factor and protooncogene Scl/Tal1 in leukemia-initiating cells (LIC). We implicate SCL/TAL1 as indirect phosphorylation target of BCR-ABL1 and as a negative transcriptional regulator of CD44 expression. We show that increased SCL/TAL1 expression is associated with improved outcome in human CML. These data demonstrate the BCR-ABL1-specific, cell-intrinsic pathways leading to altered interactions with the vascular niche via the modulation of adhesion molecules - a strategy therapeutically exploitable in future.
Rhabdomyosarcoma (RMS) is the most frequent pediatric soft-tissue sarcoma comprising two major subtypes – the alveolar and the embryonal rhabdomyosarcoma. The current therapeutic regime is multimodal including surgery, radiation and chemotherapy with cytostatic drugs. Although the prognosis for RMS patients has steadily improved to a 5-year overall survival rate of 70% for ERMS and 50% for ARMS, prognosis for subgroups with primary metastases or relapsed patients is still less than 25%, highlighting the need for development of new therapies for these subgroups. Since cancer cells are addicted to their cancer promoting transcriptional program, remodeling transcription by targeting bromodomain and extraterminal (BET) proteins has emerged as compelling anticancer strategy. However, in many cancer types BET inhibition was proved cytostatic but not cytotoxic emphasizing the need for combination protocols.
In this study we identify a novel synergistic interaction of the BET inhibitor JQ1 with p110α-isoform-specific Phosphoinositid-3-Kinase (PI3K) inhibitor BYL719 (Alpelisib) to induce mitochondrial apoptosis and global reallocation of BRD4 to chromatin. At first, we showed that JQ1 single treatment had cytostatic effects at nanomolar concentrations and inhibited MYC and Hedgehog (Hh) signaling in RMS known to promote proliferation of RMS. However, JQ1 single treatment barely induced cell death in RMS cells even at concentrations of up to 20 µM (< 20% cell death). Thus, we next tested combination approaches to elicit cell death. Since we previously identified synergistic cell death induction of Hh inhibition and PI3K inhibition in RMS cells we tested JQ1 in combination with the pan-PI3K/mTOR inhibitor PI-103 and the p110α-isoform-specific PI3K inhibitor BYL719. In addition, we tested JQ1 in combination with distinct HDAC inhibitors namely JNJ-26481585, SAHA (Vorinostat), MS-275 (Entinostat) and LBH-589 (Panobinostat) since the synergistic interaction of BET and HDAC inhibition has previously been described for other tumor entities.
Interestingly the synergism of cell death induction of JQ1/BYL719 co-treatment is superior to the synergism of JQ1 with pan-PI3K/mTOR inhibitor PI-103 or the tested HDAC inhibitors as confirmed by calculation of combination index. To investigate the molecular mechanisms underlying the synergy of JQ1/BYL719 co-treatment, we performed RNA-Seq and BRD4 ChIP-Seq experiments. RNA-Seq exhibited, that JQ1/BYL719 co-treatment shifted the overall balance of BCL-2 family gene expression towards apoptosis and increased gene expression of proapoptotic BMF, BCL2L11 (BIM) and PMAIP1 (NOXA) while decreasing gene expression of antiapoptotic BCL2L1 (BCL xL). These changes were verified by qRT-PCR and Western blot. Notably, BRD4 is phosphorylated upon JQ1/BYL719 co-treatment and globally reallocates BRD4 to chromatin. This BRD4 reallocation includes enrichment of BRD4 at the super-enhancer site of BMF, at the super-enhancer, typical enhancer and promoter regions of BCL2L11 (BIM) and at the PMAIP1 (NOXA) promoter, while JQ1 alone, as expected, reduces global chromatin binding of BRD4. Integration of RNA-Seq and BRD4 ChIP-Seq data underlines the transcriptional relevance of reallocated BRD4 upon JQ1/BYL719 co-treatment. Immunopreciptation studies showed, that RMS cells are initially primed to undergo mitochondrial apoptosis since BIM is constitutively bound to antiapoptotic BCL-2, BCL xL and MCL-1. JQ1/BYL719 co-treatment increased BIM expression and its neutralization of antiapoptotic BCL-2, BCL-xL and MCL-1 thereby rebalancing the ratio of pro- and antiapoptotic BCL-2 proteins in favor of apoptosis. This promotes activation of BAK and BAX resulting in caspase-dependent apoptosis. The functional relevance of proapoptotic re-balancing for the execution of JQ1/BYL719-mediated apoptosis was confirmed by individual silencing of BMF, BIM, NOXA or overexpression of BCL-2 or MCL-1, which all significantly rescued JQ1/BYL719-induced cell death. Execution of cell death by mitochondrial caspase-dependent apoptosis was veryfied by individual knockdown of BAK and BAX or caspase inhibitor N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethylketone (zVAD.fmk), which all significantly rescued JQ1/BYL719-induced cell death.
In summary, combined BET and PI3Kα inhibition cooperatively induces mitochondrial apoptosis by proapoptotic re-balancing of BCL-2 family proteins accompanied by reallocation of BRD4 to transcriptional regulatory elements of BH3-only proteins.